Eli Lilly's Oral GLP-1 Gambit: How a $65B Pharma Giant Is Engineering the Next Phase of Metabolic Dominance

Eli Lilly closed 2025 with $65.2B in revenue (+45% YoY), driven by Mounjaro and Zepbound's combined $36.5B in sales. With orforglipron—an oral GLP-1 pill that just beat Novo Nordisk's oral semaglutide in head-to-head trials—expected to launch in Q2 2026, and a $1B AI co-innovation lab with NVIDIA building drug discovery foundation models, Lilly is compounding its lead across both metabolic medicine and AI-driven R&D.

LLY · Health Care · February 28, 2026

S&P 500 Position

Lilly is the largest healthcare company in the S&P 500 by market cap, commanding roughly 15% of the Health Care Select Sector SPDR (XLV). It is the only pharmaceutical company in the index's top 10 constituents, sitting alongside mega-cap tech names like NVIDIA, Apple, and Microsoft. Its nearest pharma competitors in the index—Johnson & Johnson (~$390B), AbbVie (~$330B), and Merck (~$270B)—are each less than half Lilly's valuation. Novo Nordisk, the chief rival in GLP-1s, trades on the NYSE as an ADR but is not an S&P 500 constituent. Lilly briefly crossed the $1 trillion market cap threshold in November 2025, becoming the first pharmaceutical company to do so.

Index Weight: ~1.55% | Rank: #10 in the S&P 500 (as of January 2026)

Company Overview

Eli Lilly is executing the most aggressive product expansion in pharmaceutical history, centered on its tirzepatide molecule (marketed as Mounjaro for type 2 diabetes and Zepbound for obesity) and its oral GLP-1 successor, orforglipron. Mounjaro and Zepbound alone generated approximately $36.5 billion in 2025 revenue—more than half the company's total sales—and Lilly maintains nearly 70% share of new branded obesity prescriptions in the U.S. The oral GLP-1 race is now Lilly's central strategic bet: ACHIEVE-3 data published in The Lancet in February 2026 showed orforglipron outperformed Novo Nordisk's oral semaglutide on both blood sugar control and weight loss. Orforglipron has been submitted for regulatory review in over 40 countries, with U.S. FDA action expected in Q2 2026. Beyond incretins, Lilly is building out a diversified pipeline across oncology (Verzenio, Jaypirca, the newly approved breast cancer drug Inluriyo), neuroscience (Kisunla for Alzheimer's, now the U.S. market leader in amyloid-targeting therapies with 50%+ prescription share), and immunology (Ebglyss for atopic dermatitis, Omvoh for IBD). The company committed over $55 billion since 2020 to manufacturing buildout and issued 2026 revenue guidance of $80–83 billion—a 25% jump that implies continued volume acceleration despite low-to-mid-teens pricing headwinds from government access agreements and direct-to-consumer discounting. Market penetration within the eligible obesity population is still only mid-single digits, meaning the total addressable market remains largely untapped. Lilly's competitive moat is increasingly structural: a manufacturing scale advantage that allows it to launch orforglipron without supply constraints (unlike Novo's Wegovy shortage issues), a direct-to-patient channel (LillyDirect, now serving over 1 million patients), and an AI infrastructure investment that is unmatched in pharma. The company's January 2026 announcement of a $1 billion co-innovation AI lab with NVIDIA signals Lilly views computational biology as a durable competitive advantage, not a PR exercise.

Products & Revenue

Lilly's revenue engine is dominated by its incretin franchise—Mounjaro (tirzepatide for type 2 diabetes) and Zepbound (tirzepatide for obesity)—which together accounted for roughly 56% of 2025 revenue at approximately $36.5 billion. The remaining revenue comes from oncology (led by Verzenio at ~$6B annually), legacy diabetes products (Trulicity, Humalog, Humulin—declining), the Jardiance collaboration with Boehringer Ingelheim, and newer launches in immunology (Taltz, Ebglyss, Omvoh) and neuroscience (Kisunla). R&D spend ran at approximately 20–21% of revenue in 2025, reflecting 36 active Phase 3 programs.

Mounjaro (tirzepatide - Type 2 Diabetes) (~35%): Dual GIP/GLP-1 receptor agonist for type 2 diabetes. Q4 2025 worldwide revenue hit $7.4B (+110% YoY), with U.S. commanding 55%+ of new incretin prescriptions.

Zepbound (tirzepatide - Obesity) (~21%): Same tirzepatide molecule approved for chronic weight management. Q4 2025 U.S. revenue reached $4.2B (+122% YoY), with ~70% share of new branded obesity prescriptions. Also approved for obstructive sleep apnea.

Oncology (Verzenio, Jaypirca, Inluriyo, Retevmo) (~12%): Verzenio (CDK4/6 inhibitor for breast cancer) anchors the portfolio at ~$6B annually. Jaypirca (BTK inhibitor for CLL) and the newly approved Inluriyo (oral SERD for breast cancer) add growth vectors.

Legacy Diabetes (Trulicity, Humalog, Humulin, Jardiance) (~15%): Trulicity (GLP-1 for diabetes) is in secular decline as Mounjaro cannibalizes share. Jardiance collaboration revenue includes milestone payments from Boehringer Ingelheim. Humalog/Humulin insulin franchise is mature.

Immunology (Taltz, Ebglyss, Olumiant, Omvoh) (~8%): Taltz (IL-17A inhibitor) treats psoriasis/psoriatic arthritis. Ebglyss (lebrikizumab for atopic dermatitis) is a newer launch. Omvoh (mirikizumab) for ulcerative colitis and Crohn's grew 55% in Q4 2025.

Neuroscience (Kisunla, pipeline) (~2%): Kisunla (donanemab, anti-amyloid antibody for Alzheimer's) is early in launch but already holds 50%+ share of U.S. amyloid-targeting prescriptions. Neuroscience leadership was recently bolstered with the hire of Carole Ho from Denali Therapeutics.

Based on Q4 2025 earnings release (Feb 4, 2026) and FY2025 product-level disclosures. Percentages are approximate and derived from quarterly run-rate data.

Leadership

David A. Ricks

CEO since 2017. Ricks joined Lilly in 1996 as a business development associate and rose through international and commercial leadership roles including president of Lilly China and Lilly Bio-Medicines before becoming CEO. A Purdue BS and Indiana University Kelley MBA graduate, he has overseen a 10x increase in Lilly's market capitalization from ~$70 billion to nearly $1 trillion, driven by the bet on tirzepatide and aggressive manufacturing investment. Named Chief Executive magazine's 2025 CEO of the Year.

Daniel Skovronsky, M.D., Ph.D., Chief Scientific and Product Officer; President, Lilly Research Laboratories: Founded Avid Radiopharmaceuticals (acquired by Lilly in 2010) and now oversees all R&D plus global product strategy for Cardiometabolic, Immunology, and Neuroscience. He is the architect of Lilly's 36-program Phase 3 pipeline and led the orforglipron program through its Phase 3 gauntlet.

Diogo Rau, EVP, Chief Information and Digital Officer: Leads Lilly's digital transformation including the NVIDIA AI co-innovation lab, the AI supercomputer ('AI factory'), LillyDirect platform, and the OpenAI antimicrobial resistance collaboration. The strategic brain behind Lilly's $1B+ AI infrastructure investment.

Kenneth Custer, Ph.D., EVP and President, Lilly Cardiometabolic Health: Runs the business unit responsible for Mounjaro, Zepbound, and orforglipron—collectively the largest revenue driver in all of pharma. Oversees the commercial ramp that took incretin revenue from near-zero to $36.5B in three years.

Jacob Van Naarden, EVP and President, Lilly Oncology; Head of Corporate Business Development: Leads oncology (Verzenio, Jaypirca, Inluriyo) and now oversees all corporate M&A and business development. Previously ran Loxo@Lilly, the semi-autonomous oncology unit built from the 2019 Loxo Oncology acquisition.

Carole Ho, M.D., EVP and President, Lilly Neuroscience: Joined in late 2025 from Denali Therapeutics where she was CMO. Tasked with scaling Kisunla (donanemab) for Alzheimer's and building out Lilly's neurodegeneration pipeline—a therapeutic area the company views as a multi-decade growth vector.

The AI Angle

Building pharma's most powerful AI factory

Lilly has made the most concentrated AI infrastructure bet in the pharmaceutical industry. In January 2026, the company and NVIDIA announced a first-of-its-kind AI co-innovation lab with up to $1 billion in joint investment over five years. The lab, built on NVIDIA's BioNeMo platform and Vera Rubin architecture, is training large biomedical foundation and frontier models for molecule identification, optimization, and validation. This sits on top of an AI supercomputer Lilly announced in 2025—described as the most powerful computing infrastructure owned by any pharmaceutical company—which powers an 'AI factory' managing the full AI lifecycle from data ingestion to high-volume inference. The lab extends into physical AI and robotics for manufacturing, with NVIDIA Omniverse-based digital twins of Lilly's production lines enabling virtual stress-testing before physical changes. Lilly's partnership strategy is deliberately multi-layered. The company collaborates with OpenAI on generative AI for antimicrobial drug discovery, with Isomorphic Labs (Google DeepMind's drug discovery spinout) on asset generation, with insitro on ML-driven target discovery for metabolic diseases, with XtalPi on small-molecule optimization (a deal worth up to $250M), and with Insilico Medicine on end-to-end AI-powered drug candidate generation ($100M+ deal signed in November 2025). This dual approach—building internal AI capability while simultaneously licensing external AI assets—is more sophisticated than most pharma AI strategies. The company launched Lilly TuneLab in September 2025, a federated AI/ML platform that gives early-stage biotech companies access to Lilly's proprietary drug discovery models trained on over $1 billion worth of research data. TuneLab uses Rhino Federated Computing's technology to protect both Lilly's and participating companies' data—models travel to the data, not the reverse. About a dozen startups including insitro, Circle Pharma, Firefly Bio, and Superluminal Medicines have joined. This is a strategic flywheel: participating companies contribute training data that improves Lilly's models, while Lilly gains visibility into external innovation. Diogo Rau, Lilly's CIDO, and Ramesh Durvasula, SVP of R&D IT, lead the technical execution. Durvasula has articulated Lilly's vendor selection philosophy bluntly: they require AI partners to demonstrate model effectiveness without accessing Lilly's proprietary data. Lilly's AI initiatives have reportedly saved approximately 1.4 million hours of human work, with a target to double that. The applications span content automation for regulatory submissions (GenAI-generated patient narratives), AI-optimized clinical trial site selection, multimodal data integration (genomics, digital health, imaging, medical records), and scientific AI agents for researcher collaboration. The risk is execution: AI-discovered drugs have had mixed results industry-wide, and Lilly's compute-heavy strategy requires sustained capital commitment. But with 36 active Phase 3 programs and an R&D budget north of $13 billion, Lilly has the pipeline volume to make AI-driven efficiency gains compound.

Financial Snapshot

Revenue (TTM): $65.2B — FY2025 | Net Income: $20.6B net income (TTM)

Margins: Gross ~83%, operating ~42-44% (non-GAAP performance margin), net 31.7%

Lilly's financial trajectory is unlike any large-cap pharma in history: 45% revenue growth at $65B scale, with guidance for another 25% to $80–83B in 2026. The company is reinvesting aggressively—R&D spend was ~20% of revenue, manufacturing capex continues to scale—while maintaining 83%+ gross margins. The 2026 EPS guidance of $33.50–$35.00 (non-GAAP) represents ~45% growth over 2025's $24.21, though pricing headwinds (government access deals, Medicaid, DTC discounting) will pressure realized prices by low-to-mid-teens. Capital allocation favors pipeline and manufacturing over buybacks, a bet on compounding organic growth rather than financial engineering.

1-Year Performance

LLY trades at $1,051.99, up approximately 19% over the past 12 months, outperforming the S&P 500's ~14% return over the same period.

The stock's 52-week range tells the story of a dramatic volatility arc: LLY plunged to $624 in August 2025 amid broader pharma sector rotation and concerns about GLP-1 pricing pressure, then rallied 82% to its January 2026 high as Q3 and Q4 earnings beat estimates, orforglipron Phase 3 data delivered across multiple trials, and the $80–83B 2026 guidance blew past the $77.6B consensus. The February 2026 ACHIEVE-3 publication in The Lancet—showing orforglipron's superiority over oral semaglutide—and Novo Nordisk's warning of up to 13% sales decline provided further tailwinds for Lilly's relative valuation thesis.

Recent News

Fun Fact: Orforglipron, the oral GLP-1 pill that could become Lilly's next mega-blockbuster, was not invented in Indianapolis. It was discovered by Chugai Pharmaceutical in Japan and licensed by Lilly in 2018 for a deal whose terms were never publicly disclosed. What makes it architecturally unique is that it is a non-peptide small molecule—unlike Novo's oral semaglutide, which is a peptide packaged with an absorption enhancer. This means orforglipron can be taken without food or water restrictions and is dramatically easier to manufacture at scale, which is why Lilly has expressed confidence it can launch without the supply constraints that plagued Wegovy. The internal development code was LY3502970.